Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Patients with relapsing multiple sclerosis (RMS) achieved No Evidence of Disease Activity more frequently if they had received long-term continuous ozanimod therapy than if they had received interferon or transitioned from interferon to ozanimod, a post-hoc analysis of the phase 3 RADIANCE trial and the open-label extension DAYBREAK study showed.